Therapeutic Potential for Cannabinoids and Their Receptors
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (22 January 2024) | Viewed by 13766
Special Issue Editors
Interests: medicinal chemistry; drug design; ligand–protein binding; molecular interactions; molecular modeling; hit identification; lead optimization
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; drug discovery; chemical synthesis; PROTAC; anticancer agents; cancer metabolism; endocannabinoid system
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; drug discovery; chemical synthesis; structure–activity relationship of bioactive compounds; cannabinoids; CB2R/CB1R ligands; allosteric modulators; bitopic ligands; natural products; polyphenols
Special Issues, Collections and Topics in MDPI journals
Interests: secondary metabolites; ethnopharmacology; abiotic stress; abiotic stress tolerance; cannabis sativa; cannabaceae; medical marijuana; phytocannabinoids; CB1 receptor; cannabidiol; tetrahydrocannabinol; CB2 receptor; cannabinoids; cannabinoid receptor agonists; cannabinoid receptor antagonists; cannabinoid receptor modulators
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce the launch of a new Special Issue of the journal Pharmaceuticals on the subject of cannabinoids titled “Therapeutic Potential for Cannabinoids and their Receptors”. We sincerely invite you to submit either a review or a research paper to this Special Issue, towards the goal of establishing a collection of papers to provide a cutting-edge view for scholars in the field.
The literature suggests that natural cannabinoids from Cannabis Sativa present several promising therapeutic effects. Studies aimed at understanding the pharmacology and the interactions with their putative targets, namely cannabinoid receptors CB1 (CB1R) and CB2 (CB2R), have been developed in the last 30 years leading to the synthesis of new series of CB1R/CB2R ligands, either selective or unselective, with different behavior. The strong clinical limitation of cannabinoids is represented by their side effects; however, in the last few years, new strategies have been found to overcome this issue.
The purpose of this Special Issue is to publish original research papers or relevant updates to the literature on recent advancements and challenges in the study of cannabinoids and in the design of new CB1R and/or CB2R ligands. This will include the identification of new lead compounds, the investigation of their mechanism of action and signaling pathways, and their potential therapeutical applications, with the aim of highlighting the diversity and innovation of this research field.
Sincerely,
Prof. Dr. Tiziano Tuccinardi
Prof. Dr. Carlotta Granchi
Dr. Francesca Gado
Dr. Andrea Mastinu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cannabinoids
- cannabinoid receptors
- chemical synthesis
- biological activity
- endocannabinoid system
- cannabinoid receptor ligands
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.